Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Mao, Qunying ^a   Dong, Chenghong ^b   Li, Xiuling ^c   Gao, Qiang ^d   Guo, Zengbing ^e   Yao, Xin ^a   Wang, Yiping ^a   Gao, Fan ^a   Li, Fengxiang ^a   Xu, Miao ^a   Yin, Weidong ^d   Li, Qihan ^e   Shen, Xinliang ^c   Liang, Zhenglun ^a   Wang, Junzhi ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b INSTITUTE OF MEDICAL BIOLOGY   (China)

^c NATIONAL VACCINE AND SERUM INSTITUTE   (China)

^d Sinovac Biotech Co Ltd   (China)

^e Hualan Biological Engineering Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS EV71 VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; INOCULATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SEROCONVERSION; SURVIVAL RATE; VIRUS STRAIN;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

HUMAN ENTEROVIRUS 71; MUS;

EID: 84867011841     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046043     Document Type: Article

References (44)

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778-790.
2. Yi L, Lu J, Kung HF, He ML, (2011) The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol 37: 313-327.
3. McMinn PC, (2002) An overview of the evolution of enterovirus 71 and its clinical and public health signifi cance. FEMS Microbiol Rev 26: 91-107.
4. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT, (2007) An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77: 188-191.
5. Ministry of Health of the People's Republic of China website. Available: http://www.moh.gov.cn/publicfiles/business/htmlfiles/wsb/pyqxx/list.htm. Accessed 2012 Aug 30.
6. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31: 678-683.
7. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, et al. (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, Southern Vietnam, 2005. Emerg Infect Dis 13: 1733-1741.
8. Tan X, Huang X, Zhu S, Chen H, Yu Q, et al. (2011) The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 6: e25662.
9. Kim KH, (2010) Enterovirus 71 infection: An experience in Korea, 2009. Korean J Pediatr 53: 616-622.
10. Ma E, Lam T, Chan KC, Wong C, Chuang SK, (2010) Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001-2009. Jpn J Infect Dis 63: 422-426.
11. Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, et al. (2005) Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between1998 and 2003. J Clin Microbiol 43: 6171-6175.
12. Chua KB, Kasri AR, (2011) Hand Foot and Mouth Disease Due to Enterovirus 71 in Malaysia. Virol Sin 26: 221-228.
13. Wang SM, Ho TS, Lin HC, Lei HY, Wang JR, et al. (2012) Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis 31: 1219-1224.
14. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386-9395.
15. Liu CC, Lian WC, Butler M, Wu SC, (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19-24.
16. Ong KC, Devi S, Cardosa MJ, Wong KT, (2010) Formadehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661-665.
17. Chen HF, Chang MH, Chiang BL, Jeng ST, (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: 2944-2951.
18. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
19. Tung W, Bakar SA, Sekawi Z, Rosli R, (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic vaccines and therapy 5: 6.
20. Chiu CH, Chu C, He CC, Lin TY, (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and Infection 8: 1671-1678.
21. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K, (2006) Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. Journal of Medical Virology 78: 1096-1104.
22. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
23. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30 (22): 3295-303.
24. Clinical Trials website. Available: http://clinicaltrials.gov/ct2/show/NCT01268787?term=NCT01268787&rank=1. Accessed 2012 Aug 30.
25. Clinical Trials website. Available: http://clinicaltrials.gov/ct2/show/NCT01376479?term=NCT01376479&rank=1. Accessed 2012 Aug 30.
26. Mao QY, Li N, Yu X, Yao X, Li FX, et al. (2011) Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 157: 37-41.
27. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29: 4829-4838.
28. Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269-6275.
29. Jia H, Cai F, Gao Q, Zhang JS, Jing SR, (2010) Development of A Quantitative ELISA Method for EV71 Antigen. Chin J Biologicals 23: 87-90.
30. Liang ZL, Mao QY, Gao Q, Li XL, Dong CH, et al. (2011) Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 29: 9668-9674.
31. Grandien M, Fosgren M, Ehrnet A (1995) Enterovirua. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington, DC: American Public Health Association. pp. 279-298.
32. Mao QY, He P, Yu X, Li N, Hao CS, (2010) Laboratory Evaluation of Method for Determination of Neutralizing Antibody against Human Enterovirus 71. Chin J Biologicals 23: 885-888.
33. Manual for the virological investigation of polio. Available: http://whqlibdoc.who.int/hq/1997/WHO_EPI_GEN_97.01.pdf. Accessed 2007 Nov 25.
34. Martin A Hamilton, (1979) Robust estimates of the ED50. Journal of the American Statistical Association 74: 344-354.
35. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523-528.
36. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, et al. (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109: e88-e93.
37. Lee MS, Chang LY, (2010) Development of enterovirus 71 vaccines. Exerpt Rev. Vaccines 9: 149-156.
38. Mao QY, Yang ZW, Yu X, Jing Q, He P, et al. (2009) Epidemic Tendency of Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A 16 in Infants in Rural Area of Kaifeng City, Henan Province, China. Chin J Biologicals 22: 911-913.
39. Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods 176: 60-68.
40. Wang LC, Tang SQ, Li YM, Zhao HL, Dong CH, et al. (2010) A Comparison of the Biological Characteristics of EV71 C4 Subtypes from Different Epidemic Strains. Virol Sin 25: 98-106.
41. Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 30: 703-711.
42. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362-4372.
43. White JL, Hem SL (2000) Characterization of aluminum-containing adjuvants. In Brown F, Corbel M, Griffiths E, eds. Physico-Chemical procedures for the Characterization of vaccines. Basel, karger. pp. 217-228.
44. Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL, (1990) Aluminum compounds used as adjuvants in vaccines. Pharm Res 7: 1282-1288.